Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

被引：0
|
作者：
Franck Morschhauser
Martin J. S. Dyer
Harriet S. Walter
Alexey V. Danilov
Loic Ysebaert
Daniel James Hodson
Christopher Fegan
Simon A. Rule
John Radford
Guillaume Cartron
Krimo Bouabdallah
Andrew John Davies
Stephen Spurgeon
Nishanthan Rajakumaraswamy
Biao Li
Rita Humeniuk
Xi Huang
Pankaj Bhargava
Juliane M. Jürgensmeier
Gilles Salles
机构：
[1] GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées,Univ. Lille, CHU Lille, ULR 7365
[2] University of Leicester,Ernest and Helen Scott Haematological Research Institute
[3] City of Hope National Medical Center,WT
[4] Département d’Hématologie IUCT-Oncopole,MRC Stem Cell Institute
[5] University of Cambridge,Department of Clinical Hematology
[6] University Hospital of Wales,Hematology Clinic
[7] University of Plymouth Medical School,Cancer Research UK Centre
[8] University of Manchester and The Christie NHS Foundation Trust,Knight Cancer Institute
[9] University Hospital of Montpellier and UMR-CNRS 5535,Hospices Civils de Lyon, Department of Hematology
[10] University Hospital of Bordeaux,undefined
[11] University of Southampton,undefined
[12] Oregon Health and Science University,undefined
[13] Gilead Sciences,undefined
[14] Inc,undefined
[15] Université de Lyon,undefined
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2108 / 2113
页数：5
相关论文
共 50 条
  • [41] Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Mehta, Amitkumar
    Salles, Gilles
    Haioun, Corinne
    Munoz, Javier
    Chen, Andy I.
    Kolibaba, Kathryn
    Lu, Dan
    Yan, Mark
    Penuel, Elicia
    Hirata, Jamie
    Lee, Calvin
    Sharman, Jeff P.
    LANCET ONCOLOGY, 2019, 20 (07): : 998 - 1010
  • [42] Hepatitis B Virus Reactivation in Patients with Previously Resolved Hepatitis B Treated with Rituximab-Containing Chemotherapy for B-Cell Lymphoma
    Cakmak, Erol
    ERCIYES MEDICAL JOURNAL, 2018, 40 (01) : 28 - 34
  • [43] Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial
    Fjorden, Karin
    Ekberg, Sara
    Kuric, Nevzeta
    Smedby, Karin E.
    Lagerlof, Ingemar
    Larsen, Thomas S.
    Jorgensen, Judit M.
    de Nully Brown, Peter
    Jerkeman, Mats
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (02) : 437 - 440
  • [44] Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia
    Walker, Alison R.
    Bhatnagar, Bhavana
    Marcondes, A. Mario Q.
    DiPaolo, Julie
    Vasu, Sumithra
    Mims, Alice S.
    Klisovic, Rebecca B.
    Walsh, Katherine J.
    Canning, Renee
    Behbehani, Gregory K.
    Garzon, Ramiro
    Blachly, James S.
    Johnson, Amy J.
    Abella-Dominicis, Esteban
    Byrd, John C.
    Blum, William
    BLOOD, 2016, 128 (22)
  • [45] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Ansell, SM
    Witzig, TE
    Kurtin, PJ
    Sloan, JA
    Jelinek, DF
    Howell, KG
    Markovic, SN
    Habermann, TM
    Klee, GG
    Atherton, PJ
    Erlichman, C
    BLOOD, 2002, 99 (01) : 67 - 74
  • [46] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [47] Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia
    Fukuhara, Noriko
    Kinoshita, Tomohiro
    Yamamoto, Kazuhito
    Nagai, Hirokazu
    Izutsu, Koji
    Yamamoto, Go
    Bhargava, Pankaj
    Rajakumaraswamy, Nishan
    Humeniuk, Rita
    Mathias, Anita
    Xing, Guan
    Fukui, Masato
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1395 - 1402
  • [48] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY
    Matasar, M.
    Herrera, A. F.
    Kamdar, M.
    Mehta, A.
    Assouline, S.
    Fleury, I.
    Kim, T. M.
    Kim, W. S.
    Bosch, F.
    Radford, J.
    Flowers, C. R.
    Bu, L.
    Hong, W. -J.
    Sehn, L. H.
    HAEMATOLOGICA, 2017, 102 : 173 - 173
  • [49] Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma
    Marini, Carolina
    Baldaia, Helena
    Trigo, Fernanda
    Castillo, Jorge J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (08) : E324 - E325
  • [50] Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine plus Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)
    Sancho, Juan-Manuel
    Abrisqueta, Pau
    Kumar, Abhijeet
    Cordoba, Raul
    Tani, Monica
    Liu, Teng
    Rappold, Erica
    Langmuir, Peter
    Lopez-Guillermo, Armando
    BLOOD, 2022, 140 : 9328 - 9330
12345